Tokio Marine Asset Management Co. Ltd. Grows Stock Holdings in Abbott Laboratories (NYSE:ABT)

Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,904 shares of the healthcare product maker’s stock after buying an additional 1,904 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Abbott Laboratories were worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Rise Advisors LLC acquired a new position in Abbott Laboratories during the fourth quarter worth about $37,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in Abbott Laboratories during the third quarter worth about $40,000. Cornerstone Planning Group LLC raised its position in Abbott Laboratories by 79.4% during the third quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock worth $44,000 after acquiring an additional 201 shares during the last quarter. Legacy Financial Group LLC acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $46,000. Finally, Briaud Financial Planning Inc acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $48,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of recent analyst reports. Evercore ISI boosted their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Citigroup boosted their target price on shares of Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada lowered their target price on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, April 18th. Raymond James restated a “buy” rating and issued a $124.00 target price on shares of Abbott Laboratories in a report on Wednesday. Finally, Barclays lowered their target price on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a report on Monday. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $121.50.

Abbott Laboratories Price Performance

ABT traded down $0.70 on Wednesday, reaching $106.89. The company had a trading volume of 5,050,066 shares, compared to its average volume of 5,719,627. Abbott Laboratories has a one year low of $89.67 and a one year high of $121.64. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. The company has a fifty day moving average of $113.90 and a 200-day moving average of $107.97. The company has a market capitalization of $185.47 billion, a P/E ratio of 33.30, a PEG ratio of 2.58 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.02. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. The company had revenue of $9.96 billion during the quarter, compared to analyst estimates of $9.88 billion. During the same quarter last year, the firm posted $1.03 EPS. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. As a group, equities research analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.06%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is presently 68.54%.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 42,500 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now directly owns 65,027 shares of the company’s stock, valued at $7,315,537.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now owns 78,704 shares of the company’s stock, valued at $9,444,480. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the transaction, the executive vice president now directly owns 65,027 shares in the company, valued at approximately $7,315,537.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,435 shares of company stock valued at $6,451,298. 0.47% of the stock is currently owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.